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Abstract
Background: To prevent pre-eclampsia in populations with insuffi-
cient dietary calcium (Ca) intake, the World Health Organisation
(WHO) recommends routine Ca supplementation during antenatal
care (ANC). WHO guidelines suggest a complex dosing regimen,
requiring as many as 5 pill-taking events per day when combined with
iron and folic acid (IFA) supplements. Poor adherence may undermine
public health effectiveness, so simpler regimens may be preferable.
This trial will compare the effect of the WHO-recommended (higher-
dose) regimen vs. a simpler, lower-dose regimen on supplement con-
sumption and pill-taking behaviours in Kenyan ANC clients. 
Design and methods: This is a parallel, non-inferiority, cluster-ran-
domized trial; we examined 16 primary care health facilities in Kenya,
1047 pregnant women between 16-30 weeks gestational age. Higher-
dose regimen: 1.5 g elemental calcium in 3 separate doses (500 mg
Ca/pill) and IFA (60 mg Fe + 400 µg folic acid) taken with evening
dose. Lower-dose regimen: 1.0 g calcium in 2 separate doses (500 mg
Ca/pill) with IFA taken as above. Measurements: Primary outcome is
Ca pills consumed per day, measured by pill counts. Secondary out-
comes include IFA pills consumed per day, client knowledge, motiva-
tion, social support, and satisfaction, measured at 4 to 10 weeks post-
enrolment. Statistical analyses: Unit of randomization is the health-
care facility; unit of analysis is individual client. Intent-to-treat analy-
sis will be implemented with multi-level models to account for cluster-
ing.
Expected public health impact: If pregnant women prescribed lower
doses of Ca ingest as many pills as women prescribed the WHO-recom-
mended regimen, developing a lower-dose recommendation for ante-
natal Ca and IFA supplementation programs could save resources.
Background
Hypertensive disorders in pregnancy, including pre-eclampsia, are
major contributing factors to maternal mortality. While the pathogene-
sis of these disorders has not been fully elucidated,1 populations with
inadequate dietary calcium (Ca) intake have been shown to be at
greater risk.1,2 Two systematic reviews of randomized controlled effica-
cy trials found Ca supplementation significantly decreases preeclamp-
sia, reducing the risk of developing the condition by half.3,4
Based on this evidence, the World Health Organisation (WHO)
strongly recommends the introduction of Ca supplementation in popu-
lations with low dietary intake as part of existing and routine antena-
tal care (ANC) programs to prevent preeclampsia.5 Many ANC pro-
grams are already implementing daily iron-folic acid (IFA) supplemen-
tation to combat pregnancy-related anaemia, therefore addition of Ca
will require an integrated prescribing and counselling protocol.6 To
optimize bioavailability and efficacy, the WHO recommends 1.5-2.0 g of
elemental Ca in 3-4 divided doses, preferably taken with food. This reg-
imen should begin at 20 weeks of gestation and continue through
delivery. Furthermore, to limit potential negative iron-calcium interac-
tion, separation in the administration of Ca and IFA supplements is
suggested.5,6 However, the evidence of an interaction is inconclusive,
with some evidence that the interaction has a transient and clinically
non-significant impact.7
Integrating Ca and IFA supplementation while taking the two types
of supplements at different times adds up to 4-5 separate pill-taking
events daily (if the client is anaemic, twice daily administration of iron
supplements is the recommended therapy). This complex regimen,
while consistent with approaches tested in existing efficacy trials,
does not account for such factors as client adherence, dietary patterns,
motivation and satisfaction, which were not examined in the trials in
the systematic reviews. Previous research has shown that client med-
ication adherence decreases with an increase in regimen complexity.8
Furthermore, delivery of a regimen with high numbers of doses faces
high cost and potential logistic complexities. Other studies, while not
Significance for public health
Pre-eclampsia is a leading cause of maternal mortality. Based on clinical evi-
dence of significant reduction in risk of pre-eclampsia, the WHO recom-
mends including calcium (Ca) supplementation in antenatal care services in
settings with inadequate dietary Ca intakes. A high daily amount of Ca
administered in a complex dosing regimen is recommended to maximize
efficacy and bioavailability. Factors such as client adherence, motivation,
cost and logistical complexities may undermine effectiveness when imple-
mented in public health programs. This cluster-randomized trial will com-
pare Ca supplement consumption between higher and lower-dose regimens
delivered through antenatal care in Kenya, integrated with iron-folic acid
supplementation. If a lower-dose regimen improves adherence, women’s Ca
supplement consumption may be comparable to that achieved under a com-
plex, higher-dose regimen. Evidence gained from this trial will guide public
health planning for antenatal calcium supplementation programs to maxi-
mize benefits through reducing logistical, cost and adherence barriers.
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conclusive, have suggested that lower-dose Ca regimens, in particular
1.0 g daily, may be efficacious.9 This would support use of a simpler,
lower-dose regimen. In addition, removing the recommendation to sep-
arate Ca from IFA administration, given the lack of evidence of signifi-
cant clinical effects of interaction, would be a reasonable approach to
reduce the regimen complexity and its potential effects on adherence
and supplement consumption.
Objectives
This trial aims to compare the effect of a higher Ca and IFA dosing
regimen with a lower-dose regimen on supplement consumption and
pill taking behaviours among ANC clients in rural Kenya. Specifically,
we will compare a higher-dose regimen that includes 3 Ca pills and 1
IFA pill daily to a lower-dose regimen that includes 2 Ca pills and1 IFA
pill daily. We seek to determine whether the two regimens will lead to
comparable numbers of pills consumed, due to differences in adher-
ence to regimen.Primary outcome
We assessed supplement consumption at follow-up visits approxi-
mately 4-10 weeks. Average number of Ca supplements consumed per
day will be compared between women assigned the higher-dose and
lower-dose regimens.Secondary objectives
Consumption of IFA supplements is a secondary outcome, to ascer-
tain whether complexity of Ca regimen has any impact on adherence to
IFA. Data were collected on maternal, health worker, and intervention
delivery characteristics that theories predict may also influence adher-
ence to both supplements. We will assess changes in pregnant women’s
knowledge, motivation, self-efficacy, and general and adherence-spe-
cific social support, and the attitudes and satisfaction of health care
workers delivering the two regimens. These intermediate outcomes
will be used to assess the fidelity, appropriateness, and acceptability of
the Ca and IFA intervention, and to examine contextual factors that
may modify uptake and adherence.
Hypothesis
We will test the following hypothesis: the lower-dose regimen will
lead to Ca supplement consumption rates that are not inferior to (by a
margin of 0.25 pill/day) the rate of Ca supplement consumption in the
higher-dose regimen.
Design and Methods Study design
This study is a parallel, cluster-randomized, non-inferiority study
comparing two Ca and IFA dosing regimens: higher dose vs. lower dose.
The higher-dose regimen, consistent with current WHO recommenda-
tions, involves 1.5 g elemental Ca (as calcium carbonate) in 3 pill-tak-
ing events (500 mg Ca/pill) and IFA (60 mg Fe + 400 µg folic acid)
taken with the evening dose. The lower dose regimen involves 1.0 g ele-
mental Ca (as calcium carbonate) in 2 pill-taking events and IFA (60
mg Fe + 400 µg folic acid) taken with the evening dose. Total supple-
ments consumed was assessed during up to two follow-up visits from 4
to 10 weeks after enrolment. Secondary outcomes were also measured
at baseline and at follow-up.Timeline
Recruitment of study participants commenced on September 22nd
2014. Respondent follow-up was completed on June 12th 2015. Data
analysis will commence in September 2015.Setting
This study was conducted in Malava sub-county, Kakamega County
in Western Kenya. The target population consists of pregnant women
receiving antenatal care services and healthcare workers providing
such services in healthcare facilities. The location was selected in con-
sultation with Micronutrient Initiative Kenya and Ministry of Health
personnel. The county headquarters, Kakamega town, is located 52 km
north of Kisumu. Malava sub-county, located northeast of Kakamega
with a population of over 220,000, is primarily rural. The sub-county
headquarters is located in the largest town, Malava. ANC services are
provided by one sub-county referral facility in Malava, 3 health centres
providing ambulatory preventive and curative services, and 15 smaller
dispensaries providing preventive health services.Randomization, treatment allocation, and masking
Treatment was randomly allocated at the level of cluster, considering
each primary healthcare facility in Malava sub-county as a potential
cluster. There were 19 healthcare facilities providing antenatal primary
care services in the sub-county at the time of cluster selection. All
healthcare facilities with at least 60 first ANC visits according to the
2013 sub-county administrative data were selected to participate in the
study. Based on this criterion, 16 healthcare facilities were selected.
Prior to treatment allocation, we received commitment from the county
and sub-county health management teams that all selected facilities
will participate in the study and none of the selected facilities opted
out. To allocate treatment, consultants from the Cornell Statistical
Consulting Unit (CSCU) generated a roster of 16 numbered units ran-
domly allocated to two different groups A and B. Group A had been pre-
designated as higher-dose and group B as lower-dose. A member of the
collaborating team in Kenya was requested to assign serial codes 01-16
to the selected participating facilities, prior to receipt of the randomiza-
tion roster from CSCU. The randomization roster was matched to the
serial numbers to determine facility treatment allocation by the project
coordinator.
This study is open-label. Research assistants, healthcare providers
and participants are all aware of the allocated prescription regimen.
They are however unaware of the specific hypothesis of the study.Study participants
Study participants were recruited from women attending regularly
scheduled ANC visitations, on the days that have been designated as
recruitment dates at each participating primary care facility. Women
16-30 weeks gestational age were considered for inclusion. Gestational
age was assessed primarily by self-reported last menstrual period
(LMP) but where self-reported LMP differed from clinician assessment
during the ANC consultation, clinician assessment was accepted.
Exclusion criteria included age <15 years old, adequate dietary or
medicinal consumption of Ca (assessed with a dietary and medicinal
Ca consumption screening tool developed for the study), and intention
to leave the study community before 8 weeks from date of recruitment
interview.Intervention
As part of this cluster-randomized trial, the study team worked with
the sub-county health management team to integrate Ca supplementa-










tion into ANC services at all facilities in Malava sub-county. Aside from
the regimen assignment, all other interventions were similarly deliv-
ered across all healthcare facilities in the sub-county, irrespective of
participation in the cluster-randomized trial or the study arm within
this trial. These blanket interventions were: i) Direct provision of Ca
supplements to all facilities to avoid stock-outs; ii) direct stop-gap pro-
vision of iron-folic acid supplements to all facilities to avoid stock-outs;
iii) community mobilization of pregnant women to attend ANC clinics
through training and motivation of community health workers; iv)
Training ANC providers on Ca supplementation and counselling tech-
niques; v) Development and distribution of appropriate counselling
guides and job aids to all facilities; and vi) development and distribu-
tion of take-home behaviour change communication materials (i.e.,
calendar and poster) to healthcare facilities to facilitate pregnant
women’s adherence to their recommended regimen and encourage
familial support.
Health care workers from the study facilities were trained in the ran-
domly allocated treatment protocol during 4 training sessions that took
place on 4 different days at the same venue. All training sessions con-
tained modules focused on purpose, rationale, prescription regimen,
benefits and side-effects of Ca and IFA supplementation as well as
training on counselling techniques. The 4 training sessions were sim-
ilar in content except for dosing regimen for Ca supplementation.
Almost all (40/42) healthcare workers who provide ANC in the sub-
county attended a session in which the prescription regimen reflected
the treatment allocation of their cluster; the remaining did not attend
any initial session. The same set of facilitators, which included 2 mem-
bers of the sub-county health management team and 2 members of the
investigating team, delivered all training sessions. Make-up training
sessions were facilitated for 13 healthcare workers who were newly
recruited by the government during the course of the study and one of
the two healthcare workers who missed the original training. The
make-up training sessions were also consistent with the treatment
allocation for the health workers’ facilities.
The Ca supplements used in the trial were Ostocal Calcium and
Vitamin D3 film-coated tablets manufactured by Eskayef Bangladesh
Limited and purchased through Madawa Pharmaceuticals, Nairobi,
Kenya. All calcium products contained 200 IU of vitamin D per pill.Sample size
The primary outcome of this study is supplement consumption
expressed as the number of Ca pills taken per day. The inferiority mar-
gin is a mean difference of 0.25 pill consumption per day i.e the null
hypothesis of inferiority of the lower-dose regimen will be rejected if
the upper border of the confidence interval around the mean difference
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Table 1. Measures used at each interview visit with antenatal care clients in Kenya participating in a cluster randomized trial comparing
consumption of calcium supplements with higher- vs. lower-dose regimens.
Measure                                                                                                                                         Interview visit*
                                                                                                                   Enrollment                     Follow up 1                         Follow up 2
Informed consent                                                                                                                               x                                                                                                            
Inclusion/exclusion criteria                                                                                                              x                                                                                                            
Allocation of participant ID                                                                                                               x                                                                                                            
Demographic data                                                                                                                               x                                                                                                            
Knowledge transfer                                                                                                                            x                                                                                                            
Knowledge retention                                                                                                                                                                              x                                                       x
Perceived adherence barriers/facilitators                                                                                   x                                                                                                            
Experienced adherence barriers/facilitators                                                                                                                                  x                                                       x
Adverse events                                                                                                                                                                                        x                                                       x
Motivation and appropriateness                                                                                                     x                                                  x                                                       x
Self-efficacy                                                                                                                                          x                                                  x                                                       x
General social support                                                                                                                      x                                                                                                           x
Adherence specific social support                                                                                                                                                     x                                                       x
Health worker fidelity                                                                                                                        x                                                  x                                                       x
Client satisfaction                                                                                                                               x                                                  x                                                       x
3-day/30-day self-report adherence measure                                                                                                                                  x                                                       x
Supplement counts: Dispensed/Remaining                                                                                 D                                               D/R                                                  D/R
*Each interview is conducted before an antenatal care consultation, with an exit interview portion completed after the consultation. Follow-up 1 occurs 4 weeks after the enrollment interview and follow-up 2 occurs
8 weeks after enrollment. 
Figure 1. Participant flow diagram through the phases of enrol-
ment, intervention allocation, follow-up, and data analysis in a
cluster-randomized non-inferiority trial of two antenatal calcium
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in daily calcium consumption between the two study arms is below 0.25
pill. Based on preliminary data, the standard deviation of daily supple-
ment consumption is expected to be 0.9 pill/day. A sample size of 194
women per group will allow rejection of the null hypothesis that the
lower-dose regimen results in reduced average daily consumption of Ca
(by >0.25 pill) than the higher-dose regimen, assuming a standard
deviation of 0.9 pill/day, for a one-sided test with alpha of 0.05 and
power of over 0.80. Women were sampled from the 16 facilities in the
study area that reported more than 60 first ANC visits in 2013.
Assuming an intra-cluster correlation of 0.02 and an average cluster
size of 60 participants from each of the 16 eligible facilities, the design
effect equals 2.18. Therefore, 423 women/group are needed in this clus-
tered sample to achieve the same power as 194 women/group in a ran-
domized design in which all observations are independent.Measurements
A team of 6 trained interviewers recruited participants and adminis-
tered the survey questionnaires. All survey questionnaires were trans-
lated into Kiswahili and translated back into English to verify transla-
tion quality and content. The contextual appropriateness and under-
standing of the questions were assessed during pre-testing of the
instruments.
Data were collected from each participant at up to three time points,
as shown in Table 1. Recruitment days for each participating facility
were determined and communicated to staff and communities in
advance. At the enrolment visit, all ANC clients attending the facility on
the designated day were screened and consent was sought from those
found eligible for the study, prior to their ANC consultations.
Consenting clients were enrolled, a demographic survey was adminis-
tered, and they were asked to participate in an exit interview after their
ANC consultations. After the exit interview, enrolled participants were
requested to return for follow-up visits approximately 4 and 8 weeks
later (acceptable window for follow-up is 4-10 weeks). At follow-up vis-
its, participants were interviewed prior to their ANC consultations and
their remaining pills were counted. During an exit interview after the
ANC consultation, newly-received pills were counted. After the first fol-
low-up interview, participants were requested to return for a second
follow-up visit (with similar data collection activities, as shown in
Figure 1) approximately 4-6 weeks later, the final visit before exit from
the study. To determine supplement consumption, supplement counts
were measured 1-2 times between 4 and 10 weeks after enrolment.
Participants that missed follow-up visits were tracked to their homes
for supplement counts to be conducted, when traceable. Details of
adherence behaviours were assessed by self-report using a 3-day recall
record of timing of doses taken, supplemented by a 30-day recall meas-
ure of frequency of taking Ca and IFA supplements, using a 4-point
scale ranging from almost never to almost always. Self-report measures
of 3-day and 30-day recall were developed for optimal patient under-
standing and administration of the measures in the study setting. Such
self-report measures have demonstrated high correlation to an objec-
tive pill count measure in other populations.10
Several secondary outcomes were assessed during each interview.
The interviews cover a range of psycho-social constructs, including a
series of questions designed to evaluate factors most important to pill
taking behavior. Additional outcomes include pregnant women’s knowl-
edge, self-efficacy, motivation, and general and adherence-specific
social support.
Exit interviews at each visit were used to assess health care provider
fidelity to the intended protocol. These interviews sought information
about whether or not ANC clients received an adequate number of sup-
plements, as well as accurate and complete information about their
dosing regimen, the purpose, benefits, and side-effects of Ca and IFA
supplementation. Interviews also covered perceptions of the feasibility,
appropriateness, and acceptability of the intervention, and motivations
for adherence. 
The experience of the health care providers was measured with a
healthcare workers’ survey on professional characteristics; knowledge
of Ca, IFA, anaemia and pre-eclampsia; and perceptions of the feasibil-
ity, appropriateness, and acceptability of delivering Ca supplements
through ANC. Data were collected through surveys administered before
and after the training sessions, and through healthcare worker inter-
views at the midline and end of the study.Statistical analysis
This is a cluster randomized trial and outcomes will be analysed
using statistical methods that account for the hierarchical structure of
the data. Supplement consumption assessed as average number of pills
consumed/day (averaged across follow-up visits) will be the primary
dependent variable. This continuous outcome will be modelled using a
2-level linear mixed effects model to account for participants nested
within health facilities. The fixed effect will be group (higher vs. lower
dosing regimen) and the random effect will be cluster (health facility).
The null hypothesis of inferiority will be rejected if the upper bound of
the confidence interval of the fixed effect coefficient is <0.25 pills.
Analysis will be done on both intent-to-treat and per protocol bases.
Statistical analysis will be done using Stata Statistical Software: Release
14 (StataCorp. 2013).Ethical aspects
This study was reviewed and approved by the Institutional Review
Board at Cornell University and Kenyatta National Hospital and
University of Nairobi Ethics and Research Review Committee. All
respondents were given detailed information about the objectives and
purpose of the study and written informed consent was obtained from
each respondent before enrolment. This trial is registered as
NCT02238704.
Discussion
Pre-eclampsia is a leading cause of maternal mortality. Based on
meta-analysis of randomized clinical trials of Ca supplementation
showing significant reduction in risk of pre-eclampsia, the WHO rec-
ommends the inclusion of Ca supplementation in ANC services in set-
tings with inadequate dietary Ca intake. The WHO guidelines recom-
mend a high daily amount of Ca administered in divided doses, as well
as a separate administration of IFA. Implementation of this recommen-
dation would involve a complex dosing regimen, with as many as 5 sep-
arate pill-taking events per day. While this regimen is based on doses
used in available efficacy trials and is optimized for bioavailability, fac-
tors such as client adherence, motivation and satisfaction, as well as
cost and logistical complexities may undermine its effectiveness in
public health programs.9 Ca supplements are bulky, and reducing the
number of Ca pills needed would lead to significant savings in procure-
ment, shipping, and storage costs. If a lower-dose regimen improves
the feasibility of good adherence, women’s supplement consumption
may be comparable to that achieved under a complex, higher-dose reg-
imen. In this way, evidence gained from this trial could increase the
benefits of antenatal calcium supplementation in public health con-
texts, through reducing logistical, cost and adherence barriers. This
trial is not designed to measure clinical end-points. Research to direct-
ly assess impact of lower-dose Ca supplementation on clinical end-
points such as pre-eclampsia will complement findings of this trial.
Beyond regimen complexity, there are implementation concerns of
interest to policy makers and program planners within countries tasked
with translating the WHO guidelines into effective programs. Our study









is designed to shed light on issues of implementation regardless of reg-
imen. ANC has been used as a service delivery platform for reaching
pregnant women with proven interventions such as IFA supplements,
insecticide-treated nets, malaria prophylaxis and maternal immuniza-
tion. However, ANC programs have faced operational challenges and
there is a need for implementation research to ensure that introducing
Ca supplements using ANC as a platform does not displace existing
programs. This cluster-randomized trial is supplemented with addition-
al measures of acceptability, fidelity and feasibility of implementation
that will provide preliminary insights on addressing these concerns.
Providing program planners with evidence-based potential solutions to
the integration of Ca supplementation into existing programs will
accelerate policy adoption and the introduction of effective Ca supple-
mentation programs. The cluster-randomized trial is a strong design
for assessing the impact of regimen complexity on consumption of sup-
plements. The strength of this study lies in the distinction between
efficacy-optimized pill taking schemes, and effectiveness-optimized
regimens for large-scale implementation. Prior research suggests over-
ly complex pill-taking regimens result in lower adherence rates in
patients.8 Total consumption of supplements may not be significantly
reduced by a lower-dose regimen, if adherence rate to this simpler reg-
imen exceeds that for the higher-dose regimen. By evaluating this
hypothesis, this trial will provide evidence needed to facilitate transla-
tion of global policy guidance into large-scale practice.
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